Shaji K. Kumar, MD, on Clinical Implications of Changing Treatment Paradigms for Multiple Myeloma

Posted: Monday, November 22, 2021

Shaji K. Kumar, MD, of the Mayo Clinic Cancer Center, offers clinical pearls on adding a fourth drug to the induction regimen for patients with newly diagnosed multiple myeloma, the new drug classes that could improve outcomes, and how to decide whether and when to alter treatments.